Vitamin C deficiency may delay diet-induced NASH regression in the guinea pig
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Dokumenter
- Fulltext
Forlagets udgivne version, 7,82 MB, PDF-dokument
Oxidative stress is directly linked to non-alcoholic fatty liver disease (NAFLD) and the progression to steaotohepatitis (NASH). Thus, a beneficial role of antioxidants in delaying disease progression and/or accelerating recovery may be expected, as corroborated by recommendations of, e.g., vitamin E supplementation to patients. This study investigated the effect of vitamin C deficiency—often resulting from poor diets low in fruits and vegetables and high in fat—combined with/without a change to a low fat diet on NAFLD/NASH phenotype and hepatic transcriptome in the guinea pig NASH model. Vitamin C deficiency per se did not accelerate disease induction. How-ever, the results showed an effect of the diet change on the resolution of hepatic histopathological hallmarks (steatosis, inflammation, and ballooning) (p < 0.05 or less) and indicated a positive effect of a high vitamin C intake when combined with a low fat diet. Our data show that a diet change is important in NASH regression and suggest that a poor vitamin C status delays the reversion to-wards a healthy hepatic transcriptome and phenotype. In conclusion, the findings support a beneficial role of adequate vitamin C intake in the regression of NASH and may indicate that vitamin C supplementation in addition to lifestyle modifications could accelerate recovery in NASH patients with poor vitamin C status.
Originalsprog | Engelsk |
---|---|
Artikelnummer | 69 |
Tidsskrift | Antioxidants |
Vol/bind | 11 |
Udgave nummer | 1 |
ISSN | 2076-3921 |
DOI | |
Status | Udgivet - 2022 |
Bibliografisk note
Funding Information:
Conflicts of Interest: J.S.-R., K.P., G.F.S., and J.L. were partly funded by the LifePharm Centre at University of Copenhagen. The LifePharm Centre is a collaborative research effort between Novo Nordisk and University of Copenhagen. D.H.I. and M.L. are currently employed at Novo Nordisk A/S as part of the investigatory research unit of liver diseases. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results.
Funding Information:
Funding: This research was partly funded by the LifePharm Centre for in vivo pharmacology (Grant number #1001109652).
Publisher Copyright:
© 2021 by the authors. Licensee MDPI, Basel, Switzerland.
Antal downloads er baseret på statistik fra Google Scholar og www.ku.dk
ID: 289393173